ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile Inflammatory Arthritis"

  • Abstract Number: 0393 • ACR Convergence 2024

    Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA

    Marianne Kerski1, Smriti Mohan1, Cynthia Vizcaya2, Reema Sutariya3, Weibin Bao3 and Matthew Stoll4, 1University of Michigan, Ann Arbor, MI, 2Novartis Pharmaceutical Corporation, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
  • Abstract Number: 1309 • ACR Convergence 2024

    Bridging the Gap: Evaluating Ophthalmology Training Amongst Pediatric Rheumatology Fellows

    Jully Padam1, Tzielan Lee2 and Rajdeep Pooni3, and Childhood Arthritis and Rheumatology Research Alliance., 1Stanford University, Redwood City, CA, 2Stanford University School of Medicine, Palo Alto, CA, 3Stanford University, Palo Alto, CA

    Background/Purpose: The scarcity of literature surrounding ophthalmology training within non-ophthalmology specialties is striking. Chan et al. highlighted this gap revealing a discomfort among family medicine…
  • Abstract Number: 1771 • ACR Convergence 2024

    Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics

    Mireia Lopez Corbeto1, yolanda Guillen2, Irene Bonafonte3, Nuria Palau4, Raül Tortosa4, Estefanía Moreno Ruzafa1, Antonio Julia5 and Sara Marsal6, 1Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, 2Imidomics, Inc, Barcelona, Spain, 3Berufserfahrung: Helmholtz Munich, Barcelona, Spain, 4Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, 5Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 6Vall Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…
  • Abstract Number: 1915 • ACR Convergence 2024

    Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting

    Martha Delgado1, Cassidy Hernandez-Tamayo2, Melissa Wilson2 and Leanna Wise3, 1Los Angeles General Hospital/Keck Medicine of USC, Costa Mesa, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3LAGMC/Keck Medicine of USC, Los Angeles, CA

    Background/Purpose: Timely reproductive health conversations in the rheumatology outpatient setting are essential for optimal maternal-fetal health; however, the literature suggests that these conversations happen for…
  • Abstract Number: 1945 • ACR Convergence 2024

    The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates

    John Bridges1, Eileen Rife2, Randy Cron3, Livie Timmerman4, Linda McAllister5, Annelle Reed6, Carolyn Smith7, Emily Smitherman3, Matthew Stoll3, Bethany Walker5 and Melissa Mannion3, 1University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 2University of Alabama Birmingham, Vestavia Hills, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama at Birmingham, Gardendale, AL, 5Children's of Alabama, Trussville, AL, 6Children's of Alabama, Tuscaloosa, AL, 7Children's of Alabama, Birmingham, AL

    Background/Purpose: The transition period from pediatric to adult-oriented rheumatology care is a high-risk time for disease flare and poor outcomes.  We previously demonstrated implementation of…
  • Abstract Number: 0359 • ACR Convergence 2023

    Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment

    Chelsea Vallejos1, Jennifer Cooper2 and Ingrid Pan1, 1Children's Hospital Colorado, Aurora, CO, 2University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Adalimumab therapeutic drug monitoring (TDM) using established trough concentrations is not standard practice in JIA patients, unlike IBD. No specific guidelines outline a therapeutic…
  • Abstract Number: 0364 • ACR Convergence 2023

    Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis

    Adam Mayer1, Timothy G. Brandon2, Pamela F. Weiss3 and on behalf of the JAXSPERT members2, 1University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…
  • Abstract Number: 0831 • ACR Convergence 2023

    Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study

    Sarah Ringold1, George Tomlinson2, Laura Schanberg3, vincent del gaizo4, Katherine Murphy5, Brian Feldman6, Mei-Sing Ong7, Marc Natter8, Yukiko Kimura9 and For The CARRA Registry Investgators4, 1Seattle Children's Hospital, Seattle, WA, 2University of Toronto, Toronto, ON, Canada, 3Duke University School of Medicine, Durham, NC, 4CARRA, Inc, Washington, DC, 5Non-clinical, New Orleans, LA, 6The Hospital for Sick Children, Toronto, ON, Canada, 7Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, 8Harvard Medical School, Boston, MA, 9Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
  • Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium

    Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review

    Muriel Velez, Bryan Nicolalde, Kevin Moreno-Montenegro, Gabriela Carolina Carrera-Barriga, Camila Gallegos and Beatriz Leon, Universidad San Francisco de Quito, Quito, Ecuador

    Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…
  • Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium

    Using the Electronic Health Record to Identify Subjects with Rheumatic Disease

    Alysha Taxter1, Matthew Basiaga2, Rajdeep Pooni3, Caitlan Pinotti4, Lisa Buckley5 and CARRA Registry Investigators6, 1Nationwide Children's Hospital, Columbus, OH, 2Mayo Clinic, Rochester, MN, 3Stanford University, Palo Alto, CA, 4Duke, Durham, NC, 5Vanderbilt University Medical Center, Nashville, TN, 6CARRA, Washington, DC

    Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
  • Abstract Number: 020 • 2023 Pediatric Rheumatology Symposium

    Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model

    Margaret Chang1, Maryrose Hahn1, Brian Wauford1, Rachel Blaustein2, Kevin Wei2 and Peter Nigrovic1, 1Boston Children's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Most rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) patients experience episodic arthritis flares and require life-long medications to control their disease. We observed…
  • Abstract Number: 0808 • ACR Convergence 2022

    Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital

    Cristobal Pavez Perales1, Alba Torrat Novés2, José Ivorra Cortés1, Samuel Leal Rodriguez1, Anderson V Huaylla Quispe3, Carmen Riesco Bárcena2, Laura Mas Sanchez1, Pablo Muñoz Martinez4, Elena Grau García1, Elvira Vicens Bernabeu1, José Eloy Oller Rodrígez1, Francisco Miguel Ortiz Sanjuan5, Isabel Martínez-Cordellat1, Rosa Negueroles Albuixech1, Berta Lopez Montecinos6, Carmen Nájera Herranz1, Inés Cánovas Olmos1, Daniel Ramos Castro1, Inmaculada Calvo Penades7, Luis González Puig8 and José andrés Román ivorra9, 1Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, 2Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, 3Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, 4Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, 5Rheumatology Department. Hospital Universitario y Politécnico La Fe, Spain, Spain, 6Pediatric Rheumatology Unit. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, 7Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, 8Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain, 9Hospital Universitari i Politécnic la Fe, València, Spain

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the leading cause of chronic inflammatory rheumatic disease in children. It's classified into subtypes with different relative prevalences depending…
  • Abstract Number: 0867 • ACR Convergence 2022

    Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration

    Hiroto Nakano1, Emily Shuldiner2, Anne Hinks3, Marc Sudman4, Elaine Remmers5, Colleen Satorius6, Elizabeth Schmitz1, Victoria Arthur7, Patricia Woo8, Alexei Grom9, Dirk Foell10, John Bohnsack11, Marco Gattorno12, Seza Ozen13, Sampath Prahalad14, Rae Yeung15, Elizabeth Mellins2, Sheila Oliveira16, Jordi Antón17, Claudio Len18, Carol Lake19, Ly-Lan Bergeron20, Michelle Millwood21, Estefania de los santos21, Mariana Correia Marques22, Juvenile Arthritis Consortium for the Immunochip23, The Genomic Ascertainment Cohort Investigators24, INCHARGE Consortium25, Carl Langefeld26, Susan Thompson27, Wendy Thomson28 and Michael Ombrello1, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Stanford University, Stanford, CA, 3The University of Manchester, Manchester, United Kingdom, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5National Human Genome Research Institute, Bethesda, MD, 6NHGRI, NIH, Bethesda, MD, 7Boston Children's Hospital, Boston, MA, 8University College London, London, United Kingdom, 9Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10University Hospital Münster, Münster, Germany, 11University of Utah, Salt Lake City, UT, 12Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 13Hacettepe University Faculty of Medicine, Ankara, Turkey, 14Emory + Children's Pediatric Institute, Atlanta, GA, 15The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 16Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, 17Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, 18Universidade Federal de São Paulo, São Paulo, Brazil, 19NIH, Gaithersburg, MD, 20NIH/NIAMS, Vienna, VA, 21NIAMS, NIH, Bethesda, MD, 22National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, 23Juvenile Arthritis Consortium for the Immunochip, Bethesda, MD, 24The Genomic Ascertainment Cohort Investigators, Bethesda, MD, 25International Childhood Arthritis Genetics Consortium, Bethesda, MD, 26Wake Forest School of Medicine, Winston Salem, NC, 27Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, 28Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare inflammatory disease that causes spiking fever, skin rash, chronic arthritis, and inflammation of the heart and…
  • Abstract Number: 0878 • ACR Convergence 2022

    A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old

    John Gibbons1, Cynthia A. Kahlenberg1, Deanna Jannat-Khah, DrPH, MSPH1, Alexander B. Christ2, Susan Goodman1, Peter Sculco1, Mark Figgie1 and Bella Mehta3, 1Hospital for Special Surgery, New York, NY, 2Keck School of Medicine of USC, Los Angeles, CA, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Total knee arthroplasty (TKA) is rarely performed in patients under 21 years old and may be performed in this population due to conditions such…
  • Abstract Number: 1934 • ACR Convergence 2022

    Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care

    Christina Ma1, Alessana Carmona2, Habeba Talaat2, Julie Herrington3, Tania Cellucci4, Stephanie Garner2, Mark Matsos2, KAREN BEATTIE2 and Michelle Batthish2, 1McMaster University, Canada, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3ACPAC, Hamilton, ON, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada

    Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity for patients with rheumatic disease. Consequently, there has…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology